The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR/ARHP Annual Meeting 2012: Spondylarthritis Criteria Changing Landscape of the Disease

ACR/ARHP Annual Meeting 2012: Spondylarthritis Criteria Changing Landscape of the Disease

December 1, 2012 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The ASAS axial SpA criteria have been found to be reliable, with an 82.9% sensitivity rate and an 84.4% specificity rate. That high specificity greatly outpaces past criteria.2

You Might Also Like
  • New Diagnostic Criteria for Axial Spondylarthritis
  • Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium
  • ACR/ARHP Annual Meeting 2012: New Insights into Bone Erosion and Formation Heighten Prospects for Therapies
Explore This Issue
December 2012
Also By This Author
  • 7 Smartphone Tools for Rheumatologists

The ASAS classification criteria, she cautioned, were not expressly developed for diagnosis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Treatment

Home exercise can work well as a nonpharmacological treatment, Dr. van der Heijde said, but she noted that water-based therapy and supervised physical therapy are more effective. As for drug treatment, Dr. van der Heijde said, “NSAIDs are still the cornerstone of the drug treatment for patient with ankylosing spondylitis.”3

Other than that, the only other option is TNF bockers. When NSAIDs fail in AS patients, doctors can go straight to those, she said. That’s a difference from predominantly peripheral SpA, for which there are data showing that sulfasalazine and local corticosteroids also might be helpful. For AS, analgesics are probably not a good option, Dr. van der Heijde said. “There is, in fact, very little evidence that analgesics are also efficacious in patients with ankylosing spondylitis.”3

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Which NSAID is best for treating pain in AS? There is scant evidence that any one of them is better than the others. A German study comparing five types found little difference in treatment for pain.4 The evidence is solid, though, that continuous use of NSAIDs works better than on-demand use when it comes to slowing radiographic progression of the disease, she said.5 And there is even greater benefit from continuous use over on-demand use in patients with elevated CRP levels.6 The data also show that there is a clear benefit, in terms of radiographic progression, to getting a higher dose of an NSAID if the patient has syndesmophytes and elevated CRP levels.7 “But in patients with no syndesmophytes and normal CRP, there’s no difference,” Dr. van der Heijde said.

When NSAIDs fail, TNF blockers are the next step for AS patients. But when to switch? The “2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis” offers guidance.8 It suggests that switching is appropriate when two NSAIDs fail over four weeks. More could be tried, but two is enough, especially in cases of patients with active disease. Also, patients being moved to a TNF blocker should have high disease activity—a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of 4 or higher. In addition, the rheumatologist should be convinced there is active disease calling for the start of a TNF blocker.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Spondyloarthritis Tagged With: ACR/ARHP Annual Meeting, Ankylosing Spondylitis, axial spondyloarthritis (SpA), drug, patient care, radiograph, Research, Steroids, TreatmentIssue: December 2012

You Might Also Like:
  • New Diagnostic Criteria for Axial Spondylarthritis
  • Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium
  • ACR/ARHP Annual Meeting 2012: New Insights into Bone Erosion and Formation Heighten Prospects for Therapies
  • ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)